Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Capital Expenditures (2022 - 2025)

Historic Capital Expenditures for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $77000.0.

  • Taysha Gene Therapies' Capital Expenditures rose 21159.42% to $77000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $486000.0, marking a year-over-year increase of 2366.41%. This contributed to the annual value of $374000.0 for FY2024, which is 9033.34% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported Capital Expenditures of $77000.0 as of Q3 2025, which was up 21159.42% from $388000.0 recorded in Q2 2025.
  • Taysha Gene Therapies' 5-year Capital Expenditures high stood at $8.4 million for Q1 2022, and its period low was -$69000.0 during Q3 2024.
  • Moreover, its 4-year median value for Capital Expenditures was $222500.0 (2024), whereas its average is $1.8 million.
  • The largest annual percentage gain for Taysha Gene Therapies' Capital Expenditures in the last 5 years was 73541.67% (2024), contrasted with its biggest fall of 11176.47% (2024).
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Capital Expenditures stood at $2.3 million in 2022, then crashed by 99.26% to $17000.0 in 2023, then plummeted by 111.76% to -$2000.0 in 2024, then surged by 3950.0% to $77000.0 in 2025.
  • Its Capital Expenditures stands at $77000.0 for Q3 2025, versus $388000.0 for Q2 2025 and $23000.0 for Q1 2025.